JP7752929B2 - γｃサイトカイン活性の安定な調節剤 - Google Patents

γｃサイトカイン活性の安定な調節剤

Info

Publication number
JP7752929B2
JP7752929B2 JP2019554995A JP2019554995A JP7752929B2 JP 7752929 B2 JP7752929 B2 JP 7752929B2 JP 2019554995 A JP2019554995 A JP 2019554995A JP 2019554995 A JP2019554995 A JP 2019554995A JP 7752929 B2 JP7752929 B2 JP 7752929B2
Authority
JP
Japan
Prior art keywords
peptide
seq
amino acid
amino acids
cas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019554995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513020A5 (https=
JP2020513020A (ja
Inventor
ドーア，ニコラス
キュー． アル－マウサウィ，ライス
アジミ，ナーズリー
Original Assignee
バイオニズ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオニズ セラピューティクス インコーポレイテッド filed Critical バイオニズ セラピューティクス インコーポレイテッド
Publication of JP2020513020A publication Critical patent/JP2020513020A/ja
Publication of JP2020513020A5 publication Critical patent/JP2020513020A5/ja
Priority to JP2023045624A priority Critical patent/JP2023078369A/ja
Application granted granted Critical
Publication of JP7752929B2 publication Critical patent/JP7752929B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Birds (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
JP2019554995A 2017-04-07 2018-04-04 γｃサイトカイン活性の安定な調節剤 Active JP7752929B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023045624A JP2023078369A (ja) 2017-04-07 2023-03-22 γｃサイトカイン活性の安定な調節剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483210P 2017-04-07 2017-04-07
US62/483,210 2017-04-07
PCT/US2018/026125 WO2018187499A1 (en) 2017-04-07 2018-04-04 Stable modulators of gamma-c-cytokine activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023045624A Division JP2023078369A (ja) 2017-04-07 2023-03-22 γｃサイトカイン活性の安定な調節剤

Publications (3)

Publication Number Publication Date
JP2020513020A JP2020513020A (ja) 2020-04-30
JP2020513020A5 JP2020513020A5 (https=) 2021-05-13
JP7752929B2 true JP7752929B2 (ja) 2025-10-14

Family

ID=63712710

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019554995A Active JP7752929B2 (ja) 2017-04-07 2018-04-04 γｃサイトカイン活性の安定な調節剤
JP2023045624A Pending JP2023078369A (ja) 2017-04-07 2023-03-22 γｃサイトカイン活性の安定な調節剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023045624A Pending JP2023078369A (ja) 2017-04-07 2023-03-22 γｃサイトカイン活性の安定な調節剤

Country Status (8)

Country Link
US (1) US12600757B2 (https=)
EP (1) EP3606940A4 (https=)
JP (2) JP7752929B2 (https=)
KR (2) KR20240142577A (https=)
CN (1) CN110506050A (https=)
AU (3) AU2018250210B2 (https=)
CA (1) CA3054820A1 (https=)
WO (1) WO2018187499A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2665486B1 (en) 2011-01-18 2019-12-25 Bioniz, LLC Compositions for modulating gamma-c-cytokine activity
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
WO2017062685A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma - c -cytokine activity
US12600757B2 (en) 2017-04-07 2026-04-14 Bioniz Therapeutics, Inc. Peptides inhibiting gamma-c-cytokine activity and methods of use
CA3137971A1 (en) * 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
US20230203469A1 (en) * 2020-04-02 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
EP4172175A4 (en) * 2020-06-24 2024-07-24 Bioniz Therapeutics, Inc. Antagonistic peptide targeting il-2, il-9, and il-15 signaling for the treatment of cytokine-release syndrome and cytokine storm associated disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008848A1 (en) 1999-05-18 2006-01-12 Verdine Gregory L Stabilized compounds having secondary structure motifs
JP2009517405A (ja) 2005-11-28 2009-04-30 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１アンタゴニスト
JP2012508698A (ja) 2008-11-17 2012-04-12 コーベンハブンス ウニベルシテト 慢性炎症性応答の調節および自己免疫疾患の処置のためのｉｌ−４由来ペプチド
JP2012532929A (ja) 2009-07-13 2012-12-20 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二機能性のステープリングされたポリペプチドおよびそれらの使用
JP2014508140A (ja) 2011-01-18 2014-04-03 バイオニズ リミテッド ライアビリティー カンパニー γｃサイトカイン活性を調節するための組成物および方法

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700913A (en) 1982-12-15 1997-12-23 Ajinomoto Co., Inc. Unglycosylated human interleukin-2 polypeptides
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
IL80678A (en) 1985-11-19 1999-05-09 Schering Biotech Corp Human interleukin-4
US6028186A (en) 1991-06-10 2000-02-22 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7008624B1 (en) 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
ZA967182B (en) 1995-08-24 1998-05-25 Magainin Pharma Asthma associated factors as targets for treating atopic allergies including asthma and related disorders.
IL130238A0 (en) 1999-06-01 2000-06-01 Peptor Ltd Conformationally constrained backbone cyclized interleukin-6 antagonists
AU2937597A (en) 1996-05-10 1997-12-05 Biogen, Inc. Common gamma chain blocking agents
US6127387A (en) 1996-12-10 2000-10-03 Thomas Jefferson University Use of CD4-binding small molecules to inhibit immune responses
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6861227B2 (en) 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
EP0972780A1 (en) 1998-05-18 2000-01-19 Applied Research Systems ARS Holding N.V. Il-6 antagonist peptides
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
EP1284747A2 (en) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
EP1349873B1 (en) 2000-09-14 2009-04-01 Beth Israel Deaconess Medical Center, Inc. Modulation of il-2- and il-15-mediated t cell responses
CA2425506A1 (en) 2000-10-18 2002-08-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
WO2003004098A1 (en) 2001-07-06 2003-01-16 Sucampo Ag Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
CA2465268A1 (en) 2001-10-24 2003-05-01 National Jewish Medical And Research Center Three-dimensional structures of tall-1 and its cognate receptors and modified proteins and methods related thereto
ES2334338T3 (es) 2001-11-05 2010-03-09 Zymogenetics, Inc. Antagonistas de il-21.
EP2840089A1 (en) 2002-01-18 2015-02-25 ZymoGenetics, Inc. Cytokine receptor zcytor17 multimers
CA2481304A1 (en) 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans
WO2003087320A2 (en) 2002-04-09 2003-10-23 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
AU2003243189B2 (en) 2002-05-01 2008-01-24 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS
DK1531850T3 (da) 2002-06-07 2012-06-04 Zymogenetics Inc Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere
AU2002368055B2 (en) 2002-06-28 2008-09-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
AU2003251633A1 (en) 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production
US7314623B2 (en) 2002-07-15 2008-01-01 Wyeth Methods and compositions for modulating T helper (Th) cell development and function
CN1703423A (zh) 2002-10-14 2005-11-30 豪夫迈－罗氏公司 Il－15拮抗剂
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
CA2518854A1 (en) 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor
DE602004028007D1 (de) 2003-05-14 2010-08-19 Bayer Pharmaceuticals Corp Interleukin-9 antagonist-muteine und ihre pharmakologischen anwendungsverfahren
WO2004112703A2 (en) 2003-06-19 2004-12-29 Centocor, Inc. Interleukin-21 analogs
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7785580B2 (en) 2003-08-29 2010-08-31 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
EP1670501A2 (en) 2003-09-25 2006-06-21 ZymoGenetics, Inc. Methods of treating autoimmune diseases using il-21
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP1708737A2 (en) 2004-01-15 2006-10-11 Novo Nordisk A/S Use of interleukin-21 for the treatment of autoimmune diseases and allograft rejection
EP1751175B1 (en) 2004-05-05 2012-07-25 VALORISATION-RECHERCHE, Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
EP1753458A4 (en) 2004-05-19 2009-07-22 Wyeth Corp MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
RU2007102287A (ru) 2004-08-05 2008-09-10 Вайет (Us) Антагонисты активности рецептора интерлейкина-21
CU23472A1 (es) 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
WO2006105538A2 (en) 2005-03-31 2006-10-05 Centocor, Inc. Methods and compositions for treating il-21 related pathologies
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
CA2604222A1 (en) 2005-04-18 2006-10-26 Novo Nordisk A/S Il-21 variants
EP3263581B2 (en) 2005-05-17 2025-07-09 University of Connecticut Compositions and methods for immunomodulation in an organism
US8512946B2 (en) 2005-08-10 2013-08-20 Northwestern University Composite particles
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
WO2008031064A1 (en) 2006-09-07 2008-03-13 University Of South Florida Hyd1 peptides as anti-cancer agents
JP2010507382A (ja) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
US8211420B2 (en) 2006-12-21 2012-07-03 Novo Nordisk A/S Interleukin-21 variants with altered binding to the IL-21 receptor
US7910123B2 (en) 2007-09-05 2011-03-22 Warsaw Orthopedic Methods of treating a trauma or disorder of the knee joint by local administration and sustained-delivery of a biological agent
WO2009100035A2 (en) 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
EP2254998B1 (en) 2008-02-28 2015-12-23 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
WO2009132821A1 (en) 2008-04-28 2009-11-05 Giuliani International Limited Interleukin (il-21) binding proteins and methods of making and using same
US20110091515A1 (en) 2008-06-12 2011-04-21 Ramot At Tel-Aviv University Ltd. Drug-eluting medical devices
EP2356139A4 (en) * 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
US20100075329A1 (en) 2008-09-23 2010-03-25 O'toole Margot Methods for predicting production of activating signals by cross-linked binding proteins
EP2384337A1 (en) 2009-01-05 2011-11-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants
TWI541021B (zh) 2009-03-05 2016-07-11 艾伯維有限公司 Ｉｌ－１７結合蛋白
EP2406282A1 (en) 2009-03-11 2012-01-18 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
CN102753574B (zh) 2009-12-11 2015-05-20 西马生物医学计划公司 用于免疫治疗和抗肿瘤治疗的缀合物和组合物
WO2011105520A1 (ja) 2010-02-26 2011-09-01 国立大学法人 長崎大学 抗原または薬物送達複合体
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US8822642B2 (en) 2010-06-09 2014-09-02 Zymogenetics, Inc. Dimeric fusion proteins and related compositions and methods
US9084761B2 (en) 2010-07-09 2015-07-21 The Regents Of The University Of California Use of interleukin-15 to treat cardiovascular diseases
WO2012012531A2 (en) 2010-07-20 2012-01-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods featuring il-6 and il-21 antagonists
US20240043475A1 (en) 2011-01-18 2024-02-08 Bioniz, Llc Peptide conjugates
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
WO2017046200A1 (en) 2015-09-16 2017-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
WO2017062685A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma - c -cytokine activity
EP3538548A4 (en) 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
US12600757B2 (en) 2017-04-07 2026-04-14 Bioniz Therapeutics, Inc. Peptides inhibiting gamma-c-cytokine activity and methods of use
CA3137971A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
EP4172175A4 (en) 2020-06-24 2024-07-24 Bioniz Therapeutics, Inc. Antagonistic peptide targeting il-2, il-9, and il-15 signaling for the treatment of cytokine-release syndrome and cytokine storm associated disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008848A1 (en) 1999-05-18 2006-01-12 Verdine Gregory L Stabilized compounds having secondary structure motifs
JP2009517405A (ja) 2005-11-28 2009-04-30 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１アンタゴニスト
JP2012508698A (ja) 2008-11-17 2012-04-12 コーベンハブンス ウニベルシテト 慢性炎症性応答の調節および自己免疫疾患の処置のためのｉｌ−４由来ペプチド
JP2012532929A (ja) 2009-07-13 2012-12-20 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二機能性のステープリングされたポリペプチドおよびそれらの使用
JP2014508140A (ja) 2011-01-18 2014-04-03 バイオニズ リミテッド ライアビリティー カンパニー γｃサイトカイン活性を調節するための組成物および方法

Also Published As

Publication number Publication date
AU2022209272B2 (en) 2024-06-27
JP2023078369A (ja) 2023-06-06
KR20240142577A (ko) 2024-09-30
EP3606940A1 (en) 2020-02-12
US20210324029A1 (en) 2021-10-21
KR20190139245A (ko) 2019-12-17
AU2022209272A1 (en) 2022-10-20
EP3606940A4 (en) 2020-11-18
US12600757B2 (en) 2026-04-14
CA3054820A1 (en) 2018-10-11
CN110506050A (zh) 2019-11-26
AU2024203941A1 (en) 2024-07-04
JP2020513020A (ja) 2020-04-30
KR102707650B1 (ko) 2024-09-19
WO2018187499A1 (en) 2018-10-11
AU2018250210A1 (en) 2019-09-19
AU2018250210B2 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
JP7752929B2 (ja) γｃサイトカイン活性の安定な調節剤
JP2024029182A (ja) γｃサイトカイン活性を調節するための組成物および方法
JP7458336B2 (ja) γｃサイトカイン活性の調節
JP2022530677A (ja) 脱毛症および脱毛症関連障害の治療ための、γｃサイトカインのシグナル伝達の効果の調節
HK40002109A (en) Compositions and methods for modulating gamma-c-cytokine activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220808

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230322

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230322

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230404

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230412

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230418

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230609

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20230904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240205

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20241230

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251001

R150 Certificate of patent or registration of utility model

Ref document number: 7752929

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150